$11.48
0.88% day before yesterday
Nasdaq, Sep 06, 10:00 pm CET
ISIN
US75901B1070
Symbol
RGNX
Sector
Industry

REGENXBIO, Inc. Stock price

$11.48
-1.21 9.54% 1M
-12.52 52.17% 6M
-6.47 36.04% YTD
-6.19 35.03% 1Y
-23.50 67.18% 3Y
-20.36 63.94% 5Y
-18.97 62.30% 10Y
Nasdaq, Closing price Fri, Sep 06 2024
+0.10 0.88%
ISIN
US75901B1070
Symbol
RGNX
Sector
Industry

Key metrics

Market capitalization $567.38m
Enterprise Value $435.74m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 4.89
P/S ratio (TTM) P/S ratio 6.37
P/B ratio (TTM) P/B ratio 1.63
Revenue growth (TTM) Revenue growth -8.18%
Revenue (TTM) Revenue $89.04m
EBIT (operating result TTM) EBIT $-246.66m
Free Cash Flow (TTM) Free Cash Flow $-194.72m
Cash position $290.36m
EPS (TTM) EPS $-5.27
P/E forward negative
P/S forward 6.13
EV/Sales forward 4.71
Short interest 15.17%
Show more

Is REGENXBIO, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.

REGENXBIO, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

9 Analysts have issued a REGENXBIO, Inc. forecast:

9x Buy
100%

Analyst Opinions

9 Analysts have issued a REGENXBIO, Inc. forecast:

Buy
100%

Financial data from REGENXBIO, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '24
+/-
%
89 89
8% 8%
100%
- Direct Costs 55 55
1% 1%
62%
34 34
18% 18%
38%
- Selling and Administrative Expenses 63 63
4% 4%
70%
- Research and Development Expense 201 201
12% 12%
225%
-230 -230
9% 9%
-258%
- Depreciation and Amortization 17 17
4% 4%
19%
EBIT (Operating Income) EBIT -247 -247
8% 8%
-277%
Net Profit -241 -241
12% 12%
-271%

In millions USD.

Don't miss a Thing! We will send you all news about REGENXBIO, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

REGENXBIO, Inc. Stock News

Neutral
PRNewsWire
4 days ago
-  Data from pivotal dose level demonstrates long-term, sustained reductions in CSF levels of HS D2S6, a key biomarker of brain disease in MPS II -  80% of patients who received the pivotal dose discontinued intravenous enzyme replacement therapy or remained treatment-naïve -  Submission of a rolling BLA using the accelerated approval pathway on track for Q3 2024 ROCKVILLE, Md. , Sept. 3, 2024 ...
Neutral
PRNewsWire
9 days ago
ROCKVILLE, Md. , Aug. 29, 2024 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced it will participate the following upcoming investor conferences: Morgan Stanley 22nd Annual Global Healthcare Conference Fireside Chat: Thursday, September 5, 2024 at 5:35 p.m.
Neutral
PRNewsWire
12 days ago
ROCKVILLE, Md. , Aug. 27, 2024 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced data from its RGX-121 program for the treatment of mucopolysaccharidosis type II (MPS II), also known as Hunter syndrome, will be shared at the SSIEM 2024 Annual Symposium, taking place in Porto, Portugal from September 3-6, 2024.
More REGENXBIO, Inc. News

Company Profile

REGENXBIO, Inc. is a biotechnology company, which engages in the development, commercialization, and licensing of recombinant adeno-associated virus gene therapy. The company was founded by Kennth T. Mills and James M. Wilson on July 16, 2008 and is headquartered in Rockville, MD.

Head office United States
CEO Curran Simpson
Employees 344
Founded 2008
Website www.regenxbio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today